Literature DB >> 7597288

Growth control of melanoma cells and melanocytes by cytokines.

K Krasagakis1, C Garbe, C C Zouboulis, C E Orfanos.   

Abstract

Aberrant proliferation of tumor cells characterizes cancer growth. Investigations of cellular growth control mechanisms have contributed to our understanding of carcinogenesis and to the identification of compounds with specific antitumor activity. Many cytokines have been found to act on melanoma tumors, either produced by the tumor cells themselves or by infiltrating host cells. Purified cytokines allowed direct comparison of the growth response between normal human melanocytes and malignant melanoma cells. The present paper summarizes results of a series of our own experiments not yet published and data from a review of the recent literature. Proliferation of normal human melanocytes is enhanced by several cytokines, including basic fibroblast growth factor (bFGF), melanoma growth stimulatory activity (MGSA), hepatocyte growth factor (HGF), and mast cell growth factor (MGF). Melanoma cells are additionally stimulated by epidermal growth factor (EGF)/transforming growth factor alpha (TGF-alpha) and nerve growth factor (NGF). Tumor necrosis factor alpha (TNF-alpha), transforming growth factor beta 1 (TGF-beta 1), and interleukin (IL)-6 are all potent inhibitors of melanocyte growth, but they are less effective on melanoma cells or even stimulate their growth. Interferon (IFN)-alpha and IFN-gamma inhibited proliferation of melanoma cells but not of melanocytes, whereas IFN-beta showed antiproliferative effects in both cell types. These findings suggest an alteration in growth control mechanisms during melanocyte transformation and possibly play a role in melanoma pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7597288     DOI: 10.1007/978-3-642-78771-3_12

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  23 in total

1.  Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo.

Authors:  Kyle A DiVito; Valerie A Trabosh; You-Shin Chen; Yu Chen; Chris Albanese; Delphine Javelaud; Alain Mauviel; Cynthia M Simbulan-Rosenthal; Dean S Rosenthal
Journal:  Pigment Cell Melanoma Res       Date:  2010-08-25       Impact factor: 4.693

2.  Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1.

Authors:  M Yamada; K Yanaba; M Hasegawa; Y Matsushita; M Horikawa; K Komura; T Matsushita; A Kawasuji; T Fujita; K Takehara; D A Steeber; T F Tedder; S Sato
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  A case of metastatic choroidal tumor simulating a choroidal melanoma.

Authors:  Mitsuru Arima; Hiroshi Yoshikawa; Tadahisa Kagimoto; Ri-Ichiro Kohno; Tatsuro Ishibashi
Journal:  Jpn J Ophthalmol       Date:  2011-05-13       Impact factor: 2.447

4.  MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma.

Authors:  Simone Braig; Daniel W Mueller; Tanja Rothhammer; Anja-Katrin Bosserhoff
Journal:  Cell Mol Life Sci       Date:  2010-05-18       Impact factor: 9.261

5.  Different levels of TGFbeta, IL-10, IFNgamma and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells.

Authors:  C A La Porta; R Comolli
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 6.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

7.  Tumor necrosis factor-alpha induces stress fiber formation through ceramide production: role of sphingosine kinase.

Authors:  A N Hanna; L G Berthiaume; Y Kikuchi; D Begg; S Bourgoin; D N Brindley
Journal:  Mol Biol Cell       Date:  2001-11       Impact factor: 4.138

8.  IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity.

Authors:  Andrew G Sikora; Nina Jaffarzad; Yared Hailemichael; Alexander Gelbard; Spencer W Stonier; Kimberly S Schluns; Loredana Frasca; Yanyan Lou; Chengwen Liu; Helen A Andersson; Patrick Hwu; Willem W Overwijk
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

9.  Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

Authors:  Yu Yu; Hyun-Ii Cho; Dapeng Wang; Kane Kaosaard; Claudio Anasetti; Esteban Celis; Xue-Zhong Yu
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

10.  SKI knockdown inhibits human melanoma tumor growth in vivo.

Authors:  Dahu Chen; Qiushi Lin; Neil Box; Dennis Roop; Shunsuke Ishii; Koichi Matsuzaki; Tao Fan; Thomas J Hornyak; Jon A Reed; Ed Stavnezer; Nikolai A Timchenko; Estela E Medrano
Journal:  Pigment Cell Melanoma Res       Date:  2009-12       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.